MX390667B - Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. - Google Patents

Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.

Info

Publication number
MX390667B
MX390667B MX2019011620A MX2019011620A MX390667B MX 390667 B MX390667 B MX 390667B MX 2019011620 A MX2019011620 A MX 2019011620A MX 2019011620 A MX2019011620 A MX 2019011620A MX 390667 B MX390667 B MX 390667B
Authority
MX
Mexico
Prior art keywords
hdm2
interaction
regimen
hematological tumors
inhibitor
Prior art date
Application number
MX2019011620A
Other languages
English (en)
Other versions
MX2019011620A (es
Inventor
Astrid Jullion
Christophe Meille
Claire Fabre
Jens Wuerthner
Nelson Guerreiro
Sebastien Jeay
Stephane Ferretti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019011620A publication Critical patent/MX2019011620A/es
Publication of MX390667B publication Critical patent/MX390667B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un inhibidor de la interacción de HDM2-p53 (S)-5-(5-Cloro-1-metil-2-oxo-1,2-dihidro-piridin-3-il)-6-(4-cloro-fenil)-2-(2,4-dimetoxi-pirimidin-5-il)-1-isopropil-5,6-dihidro-1H-pirrolo[3,4-d]imidazol-4-ona (HDM201), o un derivado no covalente farmacéuticamente aceptable del mismo, para uso en el tratamiento de pacientes con tumores hematológicos, en donde el fármaco se administra siguiendo un régimen prolongado de dosificación baja.
MX2019011620A 2017-03-31 2018-03-29 Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. MX390667B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479397P 2017-03-31 2017-03-31
PCT/IB2018/052187 WO2018178925A1 (en) 2017-03-31 2018-03-29 Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors

Publications (2)

Publication Number Publication Date
MX2019011620A MX2019011620A (es) 2019-12-05
MX390667B true MX390667B (es) 2025-03-21

Family

ID=62025902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011620A MX390667B (es) 2017-03-31 2018-03-29 Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.

Country Status (13)

Country Link
US (2) US20200281925A1 (es)
EP (1) EP3600326B1 (es)
JP (1) JP6617208B2 (es)
KR (1) KR20190129889A (es)
CN (1) CN110392573A (es)
AU (1) AU2018242612B2 (es)
CA (1) CA3052543A1 (es)
ES (1) ES2942419T3 (es)
IL (1) IL268993A (es)
MX (1) MX390667B (es)
RU (1) RU2753527C2 (es)
TW (1) TWI771398B (es)
WO (1) WO2018178925A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
RU2762573C2 (ru) * 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
CA3123356A1 (en) 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
EP4031139A1 (en) 2019-09-16 2022-07-27 Novartis AG Use of an mdm2 inhibitor for the treatment of myelofibrosis
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
KR20220124177A (ko) 2019-12-06 2022-09-13 유니버시티 헬스 네트워크 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN105209467B (zh) * 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
TW201605450A (zh) * 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015082384A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
US9290505B2 (en) * 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
HK1251165A1 (en) * 2015-04-13 2019-01-25 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
TWI804010B (zh) * 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
ES2962460T3 (es) * 2015-08-28 2024-03-19 Novartis Ag Inhibidores de mdm2 y combinaciones de estos
RU2762573C2 (ru) * 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53

Also Published As

Publication number Publication date
KR20190129889A (ko) 2019-11-20
WO2018178925A1 (en) 2018-10-04
JP2019515018A (ja) 2019-06-06
RU2019130325A (ru) 2021-04-30
ES2942419T3 (es) 2023-06-01
CA3052543A1 (en) 2018-10-04
TW201841639A (zh) 2018-12-01
CN110392573A (zh) 2019-10-29
RU2019130325A3 (es) 2021-04-30
RU2753527C2 (ru) 2021-08-17
AU2018242612A1 (en) 2019-08-22
US20200281925A1 (en) 2020-09-10
MX2019011620A (es) 2019-12-05
JP6617208B2 (ja) 2019-12-11
TWI771398B (zh) 2022-07-21
EP3600326A1 (en) 2020-02-05
EP3600326B1 (en) 2023-01-25
IL268993A (en) 2019-10-31
AU2018242612B2 (en) 2020-05-21
US20220031697A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
PE20160011A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
NZ714963A (en) Compositions and methods for treating anemia
MX2021007391A (es) Regimenes de baja dosis extendida para inhibidores de mdm2.
PH12016502353A1 (en) Pharmaceutical composition
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
TW201613577A (en) Pharmaceutical combinations
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
BR112015012497A2 (pt) combinações farmacêuticas
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX386521B (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor